Categories: Healthcare

Atopic Eczema Treatment Market [2023-2030] Leading

The Atopic Dermatitis Global Market Report 2023 by The Business Research Company, provides atopic dermatitis market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa for the 27 major global industries. The report covers a ten-year historic period – 2010-2021, and a ten-year forecast period – 2023-2032.

Learn More On The Atopic Dermatitis Market:

https://www.thebusinessresearchcompany.com/report/atopic-dermatitis-global-market-report

According to The Business Research Company’s Atopic Dermatitis Global Market Report 2023, the market size is expected to grow from $6.48 billion in 2022 to $7.51 billion in 2023 at a compound annual growth rate (CAGR) of 15.7%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The atopic dermatitis market is expected to grow to $13.06 billion in 2027 at a CAGR of 14.9%.

The high prevalence of atopic dermatitis is expected to propel the growth of the atopic dermatitis market forward. Atopic dermatitis, also called eczema, is a skin condition that causes dryness and itchiness of the skin. The increasing prevalence of atopic dermatitis increases the need for diagnosis and treatment of the disease.

Get A Free Sample Of The Report (Includes Graphs And Tables):

https://www.thebusinessresearchcompany.com/sample_request?id=8285&type=smp

The atopic dermatitis market is segmented:

1) By Drug Class: Corticosteroids, Emollients/Moisturizers, IL-4 and PDE4 Inhibitors, Calcineurin Inhibitors, Antibiotics, Other Drug Classes

2) By Mode of Administration: Topical, Injectable, Oral

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Product innovations are a key trend gaining popularity in the atopic dermatitis market. Major companies in the market are introducing innovative products to strengthen their market position. For instance, in May 2020, Sanofi, a France-based pharmaceutical company, received FDA approval for its novel dupilumab drug Dupixent for the treatment of moderate-to-severe atopic dermatitis. It is the first and only biologic drug to receive approval for treating atopic dermatitis in children between the ages of 6 and 11. Children treated with it achieved clearer skin in just 16 weeks in the phase 3 trial, which was better than topical corticosteroids alone.

The atopic dermatitis market report table of contents includes: